Related Experiment Video
Updated: Jun 16, 2026
05:36
Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
Published on: February 23, 2024
Oral iron chelators.
1University of Pennsylvania School of Medicine, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104, USA. kwiatkowski@email.chop.edu
Hematology/Oncology Clinics of North America
|February 2, 2010
Summary
Oral chelators offer a promising alternative to parenteral therapy for managing iron overload, potentially improving patient compliance and reducing life-threatening cardiac complications. Tailoring chelation regimens enhances treatment efficacy and patient care.
Area of Science:
- Hematology
- Pharmacology
- Cardiology
Background:
- Iron overload can lead to severe organ toxicity, particularly cardiac complications and premature death.
- Parenteral chelation therapy, while effective, faces challenges with patient compliance.
- Oral chelators present a potential solution to improve adherence and outcomes.
Purpose of the Study:
- To evaluate the potential of oral chelators in managing iron overload.
- To explore strategies for improving patient compliance with chelation therapy.
- To discuss the role of chelator efficacy and side-effect profiles in treatment selection.
Main Methods:
- Review of existing literature on iron overload and chelation therapy.
- Analysis of the benefits and drawbacks of parenteral versus oral chelators.
- Consideration of factors influencing treatment regimen tailoring.
Main Results:
- Oral chelators may overcome compliance issues associated with parenteral administration.
- Chelator efficacy in iron removal (cardiac and liver) and side-effect profiles are critical for individualizing treatment.
- Expanded therapeutic options, including combination therapy, show promise.
Conclusions:
- Oral chelators can potentially improve patient outcomes in iron overload management.
- Individualized chelation regimens considering efficacy and side effects are essential.
- Broader treatment options, including combination therapies, are crucial for enhancing patient care.
Related Concept Videos
00:56Extraction: Advanced Methods
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is formed in...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:19Masking and Demasking Agents
EDTA titrations may necessitate masking and demasking agents to temporarily protect a particular metal ion in a mixture from the EDTA reaction. These agents facilitate the sequential analysis of the metal ions by forming stable complexes with some—but not all—metal ions during certain steps.
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on the metal...
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on the metal...
01:19Complexation Equilibria: The Chelate Effect
In complexation reactions, metal atoms or cations interact with ligands to form donor-acceptor adducts called metal complexes. Ligands that bind through one donor site are monodentate, ligands with two donor sites are bidentate, and those with more than two donor sites are polydentate ligands. For example, ethylene diamine is a bidentate ligand that binds through two nitrogen donor atoms, forming a five-membered ring. EDTA is a polydentate ligand that binds through four oxygen and two nitrogen...
01:22EDTA: Chemistry and Properties
Polydentate ligands are most widely used in complexometric titrations because they form more stable complexes with the metal ions than mono- or bidentate ligands due to the chelate effect. Examples of polydentate ligands are ethylenediaminetetraacetic acid (EDTA), crown ethers, and cryptands. The most important feature of optimal polydentate ligands is the ability to form 1:1 complexes in a single-step process. Amino carboxylic acid derivatives are frequently used as complexing agents. EDTA is...
01:26EDTA: Auxiliary Complexing Reagents
EDTA titrations are usually carried out in highly basic conditions, where the fully deprotonated form of EDTA, Y4−, actively complexes with the free metal ions in the solution. Several metal ions precipitate as hydrous oxide (hydroxides, oxides, or oxyhydroxides) under these conditions, lowering the concentration of free metal ions in the solution. For this reason, auxiliary complexing agents or ligands such as ammonia, tartrate, citrate, or triethanolamine are used in EDTA titrations to...